Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets

Rhea-AI Summary

Dyadic (NASDAQ: DYAI) announced an expansion of its strategic collaboration with Fermbox Bio to broaden manufacture, commercialization, and dual-sourcing of Dyadic-developed animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets.

Key elements include Fermbox manufacturing multiple Dyadic-origin products at commercial scale, co-commercialization rights globally, inclusion of Fermbox-developed products into the joint portfolio, dual-sourcing via C1, Dapibus™ or alternative microbial systems, and a jointly managed, continuously updated product pipeline to accelerate development and shorten commercialization timelines.

Positive

• Commercial-scale manufacturing of multiple Dyadic-origin products by Fermbox
• Global co-commercialization rights to jointly bring products to market
• Dual-sourcing flexibility across C1, Dapibus™, or alternative microbial systems
• Integration of Fermbox-developed products into the joint commercial portfolio

Negative

• None.

Market Reality Check

$0.8969 Last Close

Volume Volume 79,167 vs 20-day average 536,080 (relative volume 0.15) ahead of this news. low

Technical Shares traded below the 200-day MA, with price at 0.9092 vs MA 1.07 before this announcement.

Peers on Argus

Before this news, DYAI was up 10.02% while close biotech peers like LSB (-20.62%) and ESLA (-7.91%) were down and others (ANTX, CASI) were flat, indicating a stock-specific move rather than a sector-wide shift.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 15	Commercial partnership	Positive	-9.3%	New Opes Diagnostics deal to commercialize recombinant growth factors and media proteins.
Dec 01	Development agreement	Positive	-1.8%	BRIG BIO-funded program for animal-free bovine alpha-lactalbumin and shared revenues.
Nov 12	Earnings update	Negative	-3.7%	Q3 2025 results with lower revenue and wider net loss versus prior year.
Nov 10	Technology license	Positive	+6.9%	CRISPR/Cas9 license to enhance C1 and Dapibus bioproduction platform engineering.
Oct 29	Earnings scheduling	Neutral	-2.6%	Announcement of date and access details for upcoming Q3 2025 results call.

Pattern Detected

Recent partnership and commercial announcements often saw negative next-day moves, while technology licensing and some earnings updates aligned more closely with news tone.

Recent Company History

Over the last few months, Dyadic reported several strategic steps. On Oct 29, it scheduled its Q3 2025 results call, followed by a Nov 10 CRISPR/Cas9 license with ERS Genomics that drew a positive +6.91% reaction. Q3 2025 results on Nov 12 showed lower revenue and a wider loss, with shares down 3.69%. Subsequent commercial and partnership deals on Dec 1 and Dec 15 focused on animal-free proteins but saw modest to negative price reactions, framing today’s expanded Fermbox collaboration within an ongoing commercialization push.

Market Pulse Summary

This announcement expands Dyadic’s collaboration with Fermbox Bio to manufacture and co-commercialize animal-free proteins and enzymes using the C1 and Dapibus™ platforms and Fermbox’s microbial systems. It adds dual-sourcing flexibility and a jointly managed product pipeline across life science, food and nutrition, and bioindustrial markets. In recent months, Dyadic has emphasized similar partnerships and technology licenses while reporting lower revenue and a wider loss. Investors may watch for concrete revenue contributions, margin trends, and further partnership execution as key markers of progress.

Key Terms

precision fermentation technical

"developing and delivering sustainable bio-based products through precision fermentation and advanced"

Precision fermentation uses edited microbes (like yeast or bacteria) as tiny, programmable factories to produce a single, specific ingredient—such as a protein, enzyme or flavor—rather than making whole foods. Think of it like coding a vending machine to dispense one exact product on demand. For investors, it matters because it can cut production costs, speed up scale-up, reduce reliance on traditional agriculture or chemical synthesis, and create new, high-margin products that can reshape markets and regulatory pathways.

recombinant proteins medical

"particularly recombinant proteins for life sciences and food and nutrition, where demand"

Recombinant proteins are proteins produced by inserting the gene that codes for them into a host cell (like bacteria, yeast or cultured animal cells) so the cell becomes a mini factory making that exact protein. Investors care because many medicines, vaccines and diagnostic tests rely on these lab-made proteins; their commercial value depends on how easily they can be produced at scale, protected by patents, and cleared by regulators—similar to how a reliable factory and exclusive recipe affect a consumer product’s profitability.

microbial platforms technical

"Fermbox’s other microbial platforms into our joint offering, creating even greater"

Engineered microbial platforms are collections of microbes, tools and processes used to discover, develop or manufacture biological products — think of them as a programmable factory floor made of living cells. For investors, they matter because a robust platform can lower production costs, speed development, create repeatable products across programs, and become a source of intellectual property that scales revenue if regulatory approval and manufacturing quality are achieved.

biomanufacturing technical

"large-scale biomanufacturing and co-commercialization of bio-based products across life sciences,"

Making medicines, vaccines and other products using living cells or biological systems instead of purely chemical processes; it is the industrial-scale “cooking” of biological ingredients into finished medical products. Investors care because biomanufacturing determines how quickly and cheaply a company can deliver therapies, meet demand, pass regulatory checks and protect earnings—like a bakery’s ovens and recipes deciding how much bread it can sell and at what cost.

AI-generated analysis. Not financial advice.

JUPITER, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life science, food and nutrition, and bioindustrial applications, diverse commercial applications, today announced a significant expansion of its collaboration with Fermbox Bio, a biotech research & manufacturing company developing and delivering sustainable bio-based products through precision fermentation and advanced biotechnology tools. This expanded partnership broadens the range of products, platforms, and commercial opportunities the companies will jointly deliver to market. Building on their longstanding relationship, this agreement enables Fermbox Bio to manufacture and commercialize an expanding portfolio of Dyadic-developed proteins and enzymes using both the Dapibus™ and C1 expression systems. Dyadic will co-commercialize these products globally, strengthening its capacity to bring scalable, animal-free solutions to life science, food and nutrition, and bioindustrial sectors.

The agreement also allows both parties to incorporate products developed on Fermbox Bio’s proprietary microbial platforms into the joint portfolio, creating a more diverse and competitive pipeline of fermentation-derived biomolecules.

Key elements of the expanded collaboration include:

• Manufacture of multiple Dyadic-origin products by Fermbox Bio, enabling efficient production and market expansion of sustainable, animal-free proteins and enzymes.
• Dual-Sourcing flexibility, allowing both companies to supply production strains and finished products, produced via C1, Dapibus™, or alternative microbial systems.
• Integration of Fermbox-developed products into the joint commercial portfolio, where mutually agreed.
• A jointly managed, continuously updated product pipeline, allowing the companies to add new commercial opportunities as markets and customer needs evolve.

Collectively, these expanded rights and capabilities will accelerate product development, shorten commercialization timelines, and strengthen the Company’s reach into high-growth markets, particularly recombinant proteins for life sciences and food and nutrition, where demand for sustainable, economically viable animal-free ingredients continues to increase.

Joe Hazelton, President & Chief Operating Officer of Dyadic, commented:

“This expanded collaboration significantly enhances Dyadic’s go-to-market capabilities by combining our high-productivity microbial platforms with Fermbox’s robust manufacturing infrastructure. Fermbox will be producing multiple Dyadic-developed proteins and enzymes at a commercial scale, allowing us to broaden our product portfolio and accelerate commercialization across life sciences, food and nutrition, and bioindustrial markets. Equally important, this collaboration brings additional products from Fermbox’s other microbial platforms into our joint offering, creating even greater opportunities for both companies. We greatly value our partnership with Fermbox and look forward to delivering meaningful, sustainable, high-impact solutions across several industries.”

Subramani “Subbu” Ramachchandrappa, CEO of Fermbox Bio, commented:

“This expanded partnership with Dyadic reflects our commitment to build and share value by collaboratively leveraging complementary capabilities to develop and scale a broad pipeline of precision fermentation–derived bioproducts. By combining our strengths, we will accelerate Product Development, large-scale biomanufacturing and co-commercialization of bio-based products across life sciences, food and nutrition, and bio-industrial markets.”

About Dyadic Applied BioSolutions

Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information about Dyadic, please visit www.dyadic.com

About Fermbox Bio

Fermbox Bio is a biotechnology research and manufacturing company based in India with a subsidiary in USA. The company develops sustainable bio-based products using precision fermentation and advanced biotechnology, helping customers de-risk supply chains reliant on harsh chemistry, forest reserves, or animal sources. Its product portfolio of enzymes, lipids, proteins, flavors, and colors serves industries such as energy nutraceuticals, cosmeceutics, and Flavors & Fragrances. For more information visit is on www.fermbox.bio.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, including those regarding Dyadic’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of Dyadic’s clinical trial and interest in its protein production platforms, Dyadic’s research projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements involve many risks, uncertainties or other factors beyond Dyadic’s control. These factors include, but are not limited to, the following: (i) Dyadic’s history of net losses; (ii) market and regulatory acceptance of Dyadic’s microbial protein production platforms and other technologies; (iii) failure to commercialize Dyadic’s microbial protein production platforms or its other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) Dyadic’s capital needs; (vii) changes in global economic and financial conditions; (viii) Dyadic’s reliance on information technology; (ix) Dyadic’s dependence on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; and (xii) Dyadic’s ability to comply with the listing standards of the Nasdaq Stock Market LLC. For a more complete description of the risks that could cause Dyadic’s actual results to differ from its current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, Dyadic assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in Dyadic’s expectations.

Media contacts:
Dyadic Applied BioSolutions:
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com

Fermbox Bio:
Neelima Dandapat
Head of Communications
+91 8971900990
Email: Communications@fermbox.bio

FAQ

What did Dyadic announce about its expanded collaboration with Fermbox Bio on December 17, 2025?

Dyadic announced an expanded agreement letting Fermbox manufacture multiple Dyadic-origin proteins and enzymes at commercial scale and co-commercialize them globally.

How will the Dyadic–Fermbox deal affect Dyadic (DYAI) product commercialization timelines?

The agreement is designed to accelerate product development and shorten commercialization timelines through manufacturing scale and a jointly managed product pipeline.

What production systems are covered under the Dyadic and Fermbox Bio collaboration (DYAI)?

The collaboration covers production via Dyadic’s C1 and Dapibus™ platforms and allows alternative Fermbox microbial systems for dual-sourcing.

Will Fermbox Bio’s own products be part of the Dyadic (DYAI) commercial portfolio?

Yes, the expanded agreement allows mutually agreed Fermbox-developed products to be integrated into the joint commercial portfolio.

Which markets will benefit from the Dyadic and Fermbox Bio expanded partnership (DYAI)?

The partnership targets life sciences, food and nutrition, and bioindustrial markets for animal-free proteins and enzymes.

Does the Dyadic–Fermbox expansion create new manufacturing capacity for Dyadic (DYAI)?

Yes; Fermbox will produce multiple Dyadic-developed proteins and enzymes at commercial scale, increasing Dyadic’s manufacturing reach.